Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Melphalan flufenamide hydrochloride in Recurrent Multiple Myeloma: NCT06682637 Clinical Landscape Report 2026
16 October 2026
NCT06682637 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ESO-T01(EsoBiotec) in Relapse multiple myeloma: NCT06691685 Clinical Landscape Report 2026
16 October 2026
NCT06691685 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti CD19 chimeric antigen receptor T cell therapy(Beijing Boren Hospital) in Sjogren's Syndrome: NCT06688799 Clinical Landscape Report 2026
16 October 2026
NCT06688799 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal CD19 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine) in Systemic Lupus Erythematosus: NCT06691152 Clinical Landscape Report 2026
16 October 2026
NCT06691152 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD123 targeted CAR-NK cells(Chongqing Precision Biotech) in Acute Myeloid Leukemia: NCT06690827 Clinical Landscape Report 2026
16 October 2026
NCT06690827 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYS-6020 in Systemic Lupus Erythematosus: NCT06694298 Clinical Landscape Report 2026
16 October 2026
NCT06694298 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine) in Peripheral T-Cell Lymphoma: NCT06696846 Clinical Landscape Report 2026
16 October 2026
NCT06696846 clinical landscape for Peripheral T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetyladriamycin in Acute Myeloid Leukemia: NCT06697327 Clinical Landscape Report 2026
16 October 2026
NCT06697327 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06697483 Clinical Landscape Report 2026
16 October 2026
NCT06697483 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Non-Muscle Invasive Bladder Neoplasms: NCT06696794 Clinical Landscape Report 2026
16 October 2026
NCT06696794 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fludarabine Phosphate in Relapse multiple myeloma: NCT06698744 Clinical Landscape Report 2026
16 October 2026
NCT06698744 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06696183 Clinical Landscape Report 2026
16 October 2026
NCT06696183 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.